Craniopharyngiomas of Adamantinomatous Type Harbor Beta-catenin Gene Mutations
Overview
Authors
Affiliations
Craniopharyngioma is a rare tumor occurring in the sellar region comprising 3% of all intracranial tumors. To elucidate the contribution of beta-catenin gene mutation to tumorigenesis, we examined genetic alterations and expression of beta-catenin in 10 cases of adamantinomatous and 6 cases of papillary craniopharyngiomas. Beta-catenin gene mutations were found in all of the adamantinomatous and none of the papillary craniopharyngiomas. Immunohistochemically, all cases of adamantinomatous craniopharyngioma showed cytoplasmic and nuclear expression of beta-catenin. In contrast, papillary craniopharyngiomas showed exclusively membranous expression. The results suggest that adamantinomatous- and papillary-type craniopharyngiomas are not only clinicopathologically, but also genetically, distinctive variants. Mutation of the beta-catenin gene therefore seems to play an important role in the tumorigenesis of adamantinomatous craniopharyngioma. Among the adamantinomatous-type tumors, beta-catenin-positive mesenchymal cells were observed in two cases. Microdissection-based mutational analysis revealed that these mesenchymal cells also harbor the same beta-catenin gene mutations as those of epithelial cells, suggesting their tumorous nature. Thus, at least a subset of adamantinomatous craniopharyngioma is considered to be biphasic.
Targeted treatment for craniopharyngioma.
Stec N, Barker 2nd F, Brastianos P J Neurooncol. 2025; .
PMID: 39951179 DOI: 10.1007/s11060-025-04942-0.
Matsuda T, Kono T, Taki Y, Sakuma I, Fujimoto M, Hashimoto N iScience. 2024; 27(11):111068.
PMID: 39483146 PMC: 11525618. DOI: 10.1016/j.isci.2024.111068.
Insights into brain tumor diagnosis: exploring hybridization techniques.
Namiot E, Zembatov G, Tregub P Front Neurol. 2024; 15:1393572.
PMID: 39022728 PMC: 11252041. DOI: 10.3389/fneur.2024.1393572.
Genomic drivers in craniopharyngiomas: Analysis of the AACR project GENIE database.
Lehrich M, Tong C, Hsu P, Kuan C Childs Nerv Syst. 2024; 40(6):1661-1669.
PMID: 38421446 DOI: 10.1007/s00381-024-06320-z.
Integrating Systemic Therapies into the Multimodality Therapy of Patients with Craniopharyngioma.
Gritsch D, Santagata S, Brastianos P Curr Treat Options Oncol. 2024; 25(2):261-273.
PMID: 38300480 PMC: 11203386. DOI: 10.1007/s11864-023-01156-2.